US Pharma MarketingRoche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The licensing deal marks a diversification of Roche’s obesity pipeline as it seeks entry into the lucrative market.
Source: Pharmaceutical Technology